Bulk Pharmaceutical API Sources for COSYNTROPIN

Bulk Pharmaceutical API Sources for COSYNTROPIN

Vendor	Vendor Homepage	Vendor Sku	API Url
BOC Sciences		16960-16-0
eNovation Chemicals		Y1050543
THE BioTek		bt-242512
Smolecule		S1768251
CymitQuimica		CQ_16960-16-0
Santa Cruz Biotechnology, Inc.		sc-278882
J&H Chemical Co.,ltd		JH643658

COSYNTROPIN API Sourcing Analysis

Last updated: February 19, 2026

This report details the current landscape of bulk Active Pharmaceutical Ingredient (API) sourcing for Cosyntropin, a synthetic polypeptide analogue of adrenocorticotropic hormone (ACTH) [1]. The analysis focuses on identifying primary manufacturing sources, regulatory considerations, and market dynamics impacting supply chain stability.

Who Are the Primary API Manufacturers for Cosyntropin?

Manufacturing of Cosyntropin API is concentrated among a limited number of specialized peptide synthesis companies. These manufacturers possess the complex chemical synthesis capabilities required for producing high-purity polypeptide APIs.

• Bachem AG: A leading global peptide manufacturer, Bachem is a significant supplier of Cosyntropin API. The company's extensive experience in solid-phase peptide synthesis (SPPS) and purification technologies positions it as a key player [2]. Bachem operates manufacturing facilities in Switzerland, the United States, and the United Kingdom, adhering to stringent cGMP standards.

• Peptron Inc.: Based in South Korea, Peptron is another established API manufacturer with capabilities in custom peptide synthesis. The company supplies Cosyntropin API to global markets, emphasizing quality control and regulatory compliance [3]. Peptron's facilities are GMP-certified by major regulatory bodies.

• AnaSpec, Inc. (a Eurofins Scientific company): AnaSpec offers a range of custom peptide synthesis services, including the production of Cosyntropin API. With laboratories in the United States, they cater to research and commercial needs, providing peptides meeting defined purity specifications [4].

• Other Specialized Peptide Manufacturers: While the above are prominent, a broader network of smaller, specialized peptide synthesis companies globally may also offer Cosyntropin API. These can include contract manufacturing organizations (CMOs) that engage in custom synthesis projects based on client demand.

It is critical for pharmaceutical companies to conduct thorough due diligence on potential API suppliers, including site audits, quality agreements, and review of regulatory filings.

What Are the Regulatory Requirements for Cosyntropin API?

The manufacturing and supply of Cosyntropin API are governed by rigorous regulatory frameworks to ensure patient safety and product efficacy. Key regulatory considerations include:

• Current Good Manufacturing Practices (cGMP): API manufacturers must comply with cGMP guidelines as stipulated by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [5]. This includes controls over facilities, equipment, personnel, production processes, quality control, and documentation.

• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies like the FDA. A DMF contains confidential, detailed information about the facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of the drug substance [6]. Pharmaceutical companies referencing a DMF in their drug product applications gain access to this information for review by the agency.

• Inspections and Audits: Regulatory agencies conduct periodic inspections of API manufacturing sites to verify cGMP compliance. Pharmaceutical companies also perform their own audits of potential and existing API suppliers to ensure quality and reliability.

• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides harmonized guidelines on quality, safety, efficacy, and multidisciplinary topics. For API manufacturing, ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) is particularly relevant [7].

• Impurity Profiling and Control: Manufacturers must identify and control impurities in the API, including process-related impurities and degradation products. Strict specifications for impurity levels are established and validated.

• Stability Studies: Comprehensive stability studies are required to determine the shelf-life of the API under various storage conditions, ensuring its quality is maintained over time.

What is the Chemical Structure and Synthesis Process for Cosyntropin?

Cosyntropin, also known as tetracosactide or ACTH(1-24), is a synthetic polypeptide comprising the first 24 amino acids of the naturally occurring adrenocorticotropic hormone [1]. Its sequence is Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro.

The synthesis of Cosyntropin typically involves solid-phase peptide synthesis (SPPS), a widely used method for producing peptides [8]. The process generally includes the following steps:

1. Resin Loading: The first amino acid (e.g., proline for Cosyntropin) is attached to a solid resin support.
2. Deprotection: The N-terminal protecting group of the attached amino acid is removed.
3. Coupling: The next protected amino acid in the sequence is activated and coupled to the deprotected N-terminus of the growing peptide chain.
4. Washing: The resin is washed thoroughly to remove excess reagents and by-products.
5. Repetition: Steps 2-4 are repeated sequentially for each amino acid in the desired sequence (24 amino acids for Cosyntropin).
6. Cleavage: After the full peptide chain is assembled, the peptide is cleaved from the resin, and simultaneously, side-chain protecting groups are removed.
7. Purification: The crude peptide is purified, typically using reverse-phase high-performance liquid chromatography (RP-HPLC), to achieve the required purity.
8. Lyophilization: The purified peptide is often lyophilized (freeze-dried) to obtain a stable, solid powder.

The complexity of SPPS, particularly for longer peptides like Cosyntropin, necessitates precise control over reaction conditions, reagent quality, and purification parameters to ensure high yield and purity.

What are the Market Dynamics and Supply Chain Considerations for Cosyntropin API?

The market for Cosyntropin API is influenced by several factors, including demand from pharmaceutical formulators, the cost of raw materials, and the competitive landscape of API manufacturers.

• Demand Drivers: The primary driver for Cosyntropin API demand is its use in diagnostic testing, particularly for assessing adrenal function (e.g., the ACTH stimulation test for Addison's disease and congenital adrenal hyperplasia) [9]. Its use in therapeutic applications is less common but exists. The volume of diagnostic tests performed globally directly impacts API demand.

• Raw Material Availability and Cost: The cost and consistent availability of protected amino acids and other reagents used in SPPS are crucial. Fluctuations in the supply chain for these upstream materials can affect API production costs and lead times.

• Manufacturing Capacity: The specialized nature of peptide synthesis means that manufacturing capacity is not infinitely scalable. Companies specializing in peptide APIs may have dedicated production lines, but significant increases in demand could strain existing capacity.

• Geopolitical and Economic Factors: Global supply chains can be disrupted by geopolitical events, trade policies, and economic downturns. Diversifying supplier bases can mitigate some of these risks.

• Lead Times: The synthesis and purification of complex peptides like Cosyntropin can involve significant lead times, ranging from several weeks to months, depending on the manufacturer's workload and the scale of the order.

• Quality and Regulatory Compliance Costs: Maintaining high quality standards and complying with evolving regulatory requirements adds to the overall cost of API production. Manufacturers investing in advanced analytics and quality systems may command higher prices.

• Competition: While the number of large-scale peptide API manufacturers is limited, competition exists among them. Pharmaceutical companies may leverage this to negotiate pricing and secure supply agreements.

• Intellectual Property: While the Cosyntropin molecule itself is off-patent, process patents related to novel synthesis methods or purification techniques could exist and influence manufacturing approaches.

What are the Quality Control and Analytical Methods for Cosyntropin API?

Ensuring the quality of Cosyntropin API is paramount. Manufacturers employ a battery of analytical tests to confirm identity, purity, strength, and quality.

• High-Performance Liquid Chromatography (HPLC): This is the primary method for assessing the purity of Cosyntropin. RP-HPLC is used to separate the target peptide from related impurities, such as deletion sequences, truncated peptides, and oxidized forms. Purity is typically expressed as a percentage area under the curve.

• Mass Spectrometry (MS): MS techniques, often coupled with HPLC (LC-MS), are used to confirm the molecular weight of the synthesized Cosyntropin, thereby verifying its identity. MS can also help in the identification of unknown impurities.

• Amino Acid Analysis: This technique verifies the correct amino acid composition and stoichiometry of the peptide. It involves hydrolyzing the peptide into its constituent amino acids and then quantifying them using methods like ion-exchange chromatography or HPLC.

• Peptide Content/Assay: This quantifies the actual amount of Cosyntropin present in the solid API, often determined by nitrogen content analysis or quantitative HPLC using a certified reference standard.

• Water Content: Karl Fischer titration is commonly used to determine the residual water content, which can affect the stability and accurate weighing of the API.

• Counter-ion Content: If the peptide is isolated as a salt (e.g., acetate or trifluoroacetate), the counter-ion content is measured to ensure the correct salt form and stoichiometry.

• Residual Solvents: Gas chromatography (GC) is used to detect and quantify residual organic solvents from the synthesis and purification process, ensuring they are below acceptable limits as defined by ICH Q3C guidelines [10].

• Endotoxin Testing: For parenteral applications, testing for bacterial endotoxins using the Limulus Amebocyte Lysate (LAL) test is critical to ensure the API meets pyrogenicity standards.

• Sterility Testing: If the API is intended for sterile drug product manufacturing without further terminal sterilization, it may require sterility testing.

• Appearance and Solubility: Visual inspection for color and form, along with solubility tests in specified solvents, are also part of routine quality control.

Key Takeaways

• Cosyntropin API manufacturing is dominated by specialized peptide synthesis firms, including Bachem AG, Peptron Inc., and AnaSpec, Inc.
• Stringent regulatory compliance, including cGMP and DMF submissions, is mandatory for API suppliers.
• The synthesis of Cosyntropin relies heavily on solid-phase peptide synthesis (SPPS), requiring advanced chemical expertise.
• Market dynamics are driven by diagnostic test demand, raw material costs, and global supply chain vulnerabilities.
• Comprehensive quality control, utilizing techniques like HPLC, MS, and amino acid analysis, is essential for ensuring API purity and identity.

Frequently Asked Questions

• What is the typical purity specification for Cosyntropin API? Typical purity specifications for Cosyntropin API, as determined by RP-HPLC, range from ≥95% to ≥98%, depending on the grade and intended use.

• Are there any single-source risks associated with Cosyntropin API? While there are multiple manufacturers, the specialized nature of peptide synthesis can lead to concentrated production capabilities, posing potential single-source risks if a major supplier faces production issues. Diversification of suppliers is a key risk mitigation strategy.

• What is the expected shelf-life for lyophilized Cosyntropin API? Lyophilized Cosyntropin API typically has a shelf-life of 2 to 3 years when stored under recommended conditions (e.g., refrigerated and protected from light). Specific shelf-life is determined by the manufacturer's stability studies.

• How long does it typically take to obtain a supply of Cosyntropin API from a new manufacturer? The lead time for initial supply can range from 3 to 6 months, encompassing supplier qualification, auditing, sample testing, and the initial production run. Repeat orders may have shorter lead times.

• Can Cosyntropin API be sourced from manufacturers located outside of Europe and North America? Yes, Cosyntropin API can be sourced from manufacturers in various regions, including Asia. However, thorough due diligence on quality systems and regulatory compliance is critical regardless of geographic location.

Citations

[1] National Center for Biotechnology Information. (2023). PubChem Compound Summary for CID 643627, Cosyntropin. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Cosyntropin [2] Bachem AG. (n.d.). Peptides & APIs. Retrieved from https://bachem.com/ [3] Peptron Inc. (n.d.). API Manufacturing. Retrieved from https://www.peptron.com/ [4] Eurofins Scientific. (n.d.). AnaSpec | Peptides & Assays. Retrieved from https://www.anapec.com/ [5] U.S. Food and Drug Administration. (2023). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/current-good-manufacturing-practice-cgmp-regulations [6] U.S. Food and Drug Administration. (2023). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/drug-master-files-dmfs [7] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2000). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (Q7). [8] Merrifield, R. B. (1963). Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. Journal of the American Chemical Society, 85(14), 2149–2154. [9] National Institutes of Health. (n.d.). Cosyntropin Injection. Retrieved from https://medlineplus.gov/druginfo/meds/a609005.html [10] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2017). ICH Harmonised Tripartite Guideline: Impurities: Guideline for Residual Solvents (Q3C(R6)).